ZA201304042B - Spiro-oxindole mdm2 antagonists - Google Patents
Spiro-oxindole mdm2 antagonistsInfo
- Publication number
- ZA201304042B ZA201304042B ZA2013/04042A ZA201304042A ZA201304042B ZA 201304042 B ZA201304042 B ZA 201304042B ZA 2013/04042 A ZA2013/04042 A ZA 2013/04042A ZA 201304042 A ZA201304042 A ZA 201304042A ZA 201304042 B ZA201304042 B ZA 201304042B
- Authority
- ZA
- South Africa
- Prior art keywords
- spiro
- mdm2 antagonists
- oxindole mdm2
- oxindole
- antagonists
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 101150024228 mdm2 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41309410P | 2010-11-12 | 2010-11-12 | |
| US201161451968P | 2011-03-11 | 2011-03-11 | |
| US201161451958P | 2011-03-11 | 2011-03-11 | |
| US201161470992P | 2011-04-01 | 2011-04-01 | |
| PCT/US2011/060300 WO2012065022A2 (en) | 2010-11-12 | 2011-11-11 | Spiro-oxindole mdm2 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201304042B true ZA201304042B (en) | 2014-02-26 |
Family
ID=46048358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2013/04042A ZA201304042B (en) | 2010-11-12 | 2013-06-03 | Spiro-oxindole mdm2 antagonists |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8680132B2 (enExample) |
| EP (1) | EP2638046A4 (enExample) |
| JP (1) | JP2014500870A (enExample) |
| KR (1) | KR101929188B1 (enExample) |
| CN (1) | CN103298818B (enExample) |
| AR (1) | AR083849A1 (enExample) |
| AU (1) | AU2011326395B2 (enExample) |
| CA (1) | CA2817585A1 (enExample) |
| CO (1) | CO6721010A2 (enExample) |
| CR (1) | CR20130271A (enExample) |
| DO (1) | DOP2013000104A (enExample) |
| EA (1) | EA201390682A1 (enExample) |
| EC (1) | ECSP13012678A (enExample) |
| GT (1) | GT201300118A (enExample) |
| IL (1) | IL226275A0 (enExample) |
| MA (1) | MA34732B1 (enExample) |
| MX (1) | MX2013005238A (enExample) |
| NI (1) | NI201300041A (enExample) |
| NZ (1) | NZ611866A (enExample) |
| PE (1) | PE20140408A1 (enExample) |
| PH (1) | PH12013500955A1 (enExample) |
| SG (1) | SG190230A1 (enExample) |
| TW (1) | TWI535723B (enExample) |
| UA (1) | UA109464C2 (enExample) |
| UY (1) | UY33725A (enExample) |
| WO (1) | WO2012065022A2 (enExample) |
| ZA (1) | ZA201304042B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759383B2 (en) | 2005-02-22 | 2010-07-20 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| CN102712650B (zh) * | 2009-11-12 | 2015-05-20 | 密歇根大学董事会 | 螺-吲哚酮mdm2拮抗剂 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| KR20180058866A (ko) | 2010-08-13 | 2018-06-01 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| BR112013023175B1 (pt) | 2011-03-10 | 2022-11-16 | Daiichi Sankyo Company, Limited | Composto, composição farmacêutica, e, uso do composto |
| WO2012155066A2 (en) | 2011-05-11 | 2012-11-15 | Shaomeng Wang | Spiro-oxindole mdm2 antagonists |
| BR112014009418A2 (pt) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| CN112500466B (zh) | 2012-02-15 | 2022-05-03 | 艾瑞朗医疗公司 | 拟肽大环化合物 |
| WO2013123267A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| MX2015005244A (es) | 2012-11-01 | 2015-07-14 | Aileron Therapeutics Inc | Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos. |
| MX373639B (es) | 2012-12-20 | 2020-05-04 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana. |
| EP2752191A1 (en) * | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| WO2014191894A1 (en) | 2013-05-27 | 2014-12-04 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| MX2015016421A (es) | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
| PT3004112T (pt) | 2013-05-28 | 2017-12-11 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona e sua utilização no tratamento de doença |
| WO2015075665A1 (en) | 2013-11-21 | 2015-05-28 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as bet inhibitors |
| BR112016017564A8 (pt) | 2014-01-28 | 2018-04-17 | Buck Inst Res Aging | métodos e composições para matar células senescentes e para tratar doenças e transtornos associados à senescência |
| CA2945527C (en) | 2014-04-17 | 2022-05-17 | The Regents Of The University Of Michigan | Mdm2 inhibitors and therapeutic methods using the same |
| TW201613576A (en) * | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| EP3164401B1 (en) | 2014-07-03 | 2018-12-26 | Boehringer Ingelheim International GmbH | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| JP6625638B2 (ja) | 2014-08-18 | 2019-12-25 | ハドソン・バイオファーマ・インコーポレイテッド | Ｍｄｍ２阻害薬としてのスピロピロリジン |
| AU2015306128B2 (en) | 2014-08-21 | 2020-03-26 | Boehringer Ingelheim International Gmbh | New spiro[3H-indole-3,2´-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors |
| AU2015320549A1 (en) | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| AU2015320545C1 (en) | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| HRP20210960T1 (hr) | 2015-10-09 | 2021-09-03 | Boehringer Ingelheim International Gmbh | Spojevi i derivati spiro[3h-indol-3,2’-pirolidin]-2(1h)-ona kao inhibitori mdm2-p53 |
| CN105693738A (zh) * | 2016-01-14 | 2016-06-22 | 绍兴文理学院 | 3’-苯基螺[吲哚啉-3,2’-吡咯烷]-2-酮类衍生物及其制备方法和应用 |
| CA3020281A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| JP7037500B2 (ja) | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| CN107652296B (zh) * | 2016-07-26 | 2020-08-04 | 南开大学 | 螺环氧化吲哚酰腙衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用 |
| US10471154B2 (en) | 2016-08-08 | 2019-11-12 | Fei Xiao | Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof |
| CN109982702A (zh) * | 2016-11-15 | 2019-07-05 | 诺华股份有限公司 | HDM2-p53相互作用抑制剂的剂量及方案 |
| US9822128B1 (en) | 2017-06-01 | 2017-11-21 | King Saud University | Substituted spirooxindoles |
| CN109988070B (zh) * | 2017-12-29 | 2022-07-26 | 南京富润凯德生物医药有限公司 | 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用 |
| CA3087110A1 (en) * | 2017-12-29 | 2019-07-04 | Gan & Lee Pharmaceuticals | Compounds capable of being used as tumor inhibitor, preparation method thereof, and application thereof |
| EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
| KR20210072043A (ko) | 2018-10-08 | 2021-06-16 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 소분자 mdm 2 단백질 분해제 |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| MX2023005983A (es) | 2020-11-23 | 2023-08-15 | Enanta Pharm Inc | Nuevos agentes antivirales derivados de la espiropirrolidina. |
| US20250073340A1 (en) * | 2021-01-23 | 2025-03-06 | Newave Pharmaceutical Inc. | Spirocyclic mdm2 modulator and uses thereof |
| CN112876488B (zh) * | 2021-02-18 | 2021-12-21 | 苏州大学 | 螺环吲哚啉衍生物及其制备方法和应用 |
| TWI843989B (zh) | 2021-02-19 | 2024-06-01 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之支架 |
| CN115215872A (zh) * | 2021-04-15 | 2022-10-21 | 中国科学院上海药物研究所 | 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物 |
| US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| WO2023107417A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Heterocyclic antiviral agents |
| CN116283701B (zh) * | 2021-12-21 | 2025-04-22 | 中国科学院上海药物研究所 | 具有4-(取代氨甲基)-5-新戊基-n-取代基吡咯烷-2-甲酰胺结构的化合物 |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2024078370A1 (zh) * | 2022-10-13 | 2024-04-18 | 中国科学院上海药物研究所 | 具有取代苯基螺[吲哚啉-3,3'-吡咯烷]结构的小分子化合物 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219661A (en) | 1962-12-14 | 1965-11-23 | Warner Lambert Pharmaceutical | Spirooxindole and spirodehydroindole alkaloids and process therefor |
| GB1056537A (en) | 1963-07-16 | 1967-01-25 | Smith Kline French Lab | Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| RU2084449C1 (ru) | 1994-03-02 | 1997-07-20 | Всероссийский научный центр по безопасности биологически активных веществ | 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью |
| US5773455A (en) | 1996-06-28 | 1998-06-30 | Biomeasure, Incorporated | Inhibitors of prenyl transferases |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| ATE467418T1 (de) | 1997-01-20 | 2010-05-15 | Immodal Pharmaka Gmbh | Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung |
| US6114540A (en) | 1997-09-08 | 2000-09-05 | Arqule, Inc. | Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use |
| WO2000011470A1 (fr) | 1998-08-20 | 2000-03-02 | Chugai Seiyaku Kabushiki Kaisha | Procede de criblage de composes d'interet potentiel destines a un medicament contre les tumeurs |
| US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| US6831155B2 (en) | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| CN1182083C (zh) | 2001-10-08 | 2004-12-29 | 廖宜芳 | 一种杀虫灭菌的配位肥及其制造方法 |
| JP4361798B2 (ja) | 2001-12-18 | 2009-11-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｍｄｍ２インヒビターとしてのシス−イミダゾリン |
| RU2305095C2 (ru) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе |
| JP4023184B2 (ja) | 2002-03-11 | 2007-12-19 | 昭和電工株式会社 | 発光体粒子及びその製造方法並びにその用途 |
| US7514579B2 (en) | 2002-06-13 | 2009-04-07 | Johns Hopkins University | Boronic chalcone derivatives and uses thereof |
| WO2004043371A2 (en) | 2002-11-08 | 2004-05-27 | Irm Llc | Methods and compositions for modulating p53 transcription factor |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| AU2004212928A1 (en) | 2003-02-13 | 2004-09-02 | Bioveris Corporation | Deazaflavin compounds and methods of use thereof |
| US6916833B2 (en) | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| CA2534342C (en) | 2003-07-29 | 2016-05-10 | V. Ravi Chandran | Amino acid prodrugs |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| WO2005063774A1 (en) | 2003-12-22 | 2005-07-14 | Johns Hopkins University | Boronic acid aryl analogs |
| US8598127B2 (en) | 2004-04-06 | 2013-12-03 | Korea Research Institute Of Bioscience & Biotechnology | Peptides for inhibiting MDM2 function |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| KR20080027969A (ko) | 2004-05-18 | 2008-03-28 | 에프. 호프만-라 로슈 아게 | 신규 ｃｉｓ-이미다졸린 |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| CN101023074B (zh) | 2004-09-22 | 2012-10-10 | 詹森药业有限公司 | Mdm2及p53间相互作用的抑制剂 |
| US7759383B2 (en) | 2005-02-22 | 2010-07-20 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| AU2006216780B8 (en) * | 2005-02-22 | 2010-04-22 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and uses thereof |
| AU2006251138C1 (en) | 2005-05-24 | 2013-08-29 | Merck Serono Sa | Tricyclic spiro derivatives as CRTH2 modulators |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| JP5385125B2 (ja) | 2006-03-22 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ＭＤＭ２とｐ５３の間の相互作用の阻害剤 |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| US7737174B2 (en) | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| SG174107A1 (en) * | 2006-08-30 | 2011-09-29 | Univ Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
| CA2662838A1 (en) | 2006-09-21 | 2008-03-27 | F. Hoffmann-La Roche Ag | Oxindole derivatives |
| US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| CN101605798A (zh) | 2006-12-14 | 2009-12-16 | 第一三共株式会社 | 咪唑并噻唑衍生物 |
| WO2008106507A2 (en) | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
| JP2010522723A (ja) | 2007-03-29 | 2010-07-08 | ノバルティス アーゲー | 増殖性疾患の処置のための３−イミダゾリル−インドール |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| CA2699707C (en) | 2007-09-21 | 2016-05-17 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between mdm2 and p53 |
| CZ301561B6 (cs) | 2007-12-04 | 2010-04-14 | Výzkumný ústav živocišné výroby, v. v. i. | Prostredek pro prevenci a potlacování kokcidióz |
| US8134001B2 (en) | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US7723372B2 (en) | 2008-03-19 | 2010-05-25 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US7928233B2 (en) | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| CN102712650B (zh) * | 2009-11-12 | 2015-05-20 | 密歇根大学董事会 | 螺-吲哚酮mdm2拮抗剂 |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| WO2011106650A2 (en) | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| AU2011237782A1 (en) * | 2010-04-09 | 2012-10-25 | The Regents Of The University Of Michigan | Biomarkers for MDM2 inhibitors for use in treating disease |
| US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| US20120046306A1 (en) | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| US20120071499A1 (en) | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
| WO2012155066A2 (en) | 2011-05-11 | 2012-11-15 | Shaomeng Wang | Spiro-oxindole mdm2 antagonists |
-
2011
- 2011-11-11 CA CA2817585A patent/CA2817585A1/en not_active Abandoned
- 2011-11-11 JP JP2013538923A patent/JP2014500870A/ja not_active Ceased
- 2011-11-11 EP EP11840490.4A patent/EP2638046A4/en not_active Withdrawn
- 2011-11-11 KR KR1020137015168A patent/KR101929188B1/ko not_active Expired - Fee Related
- 2011-11-11 TW TW100141225A patent/TWI535723B/zh not_active IP Right Cessation
- 2011-11-11 AR ARP110104223A patent/AR083849A1/es unknown
- 2011-11-11 AU AU2011326395A patent/AU2011326395B2/en not_active Ceased
- 2011-11-11 UY UY0001033725A patent/UY33725A/es not_active Application Discontinuation
- 2011-11-11 EA EA201390682A patent/EA201390682A1/ru unknown
- 2011-11-11 MX MX2013005238A patent/MX2013005238A/es active IP Right Grant
- 2011-11-11 WO PCT/US2011/060300 patent/WO2012065022A2/en not_active Ceased
- 2011-11-11 NZ NZ61186611A patent/NZ611866A/en not_active IP Right Cessation
- 2011-11-11 UA UAA201307447A patent/UA109464C2/uk unknown
- 2011-11-11 PH PH1/2013/500955A patent/PH12013500955A1/en unknown
- 2011-11-11 US US13/294,315 patent/US8680132B2/en not_active Expired - Fee Related
- 2011-11-11 CN CN201180064853.6A patent/CN103298818B/zh not_active Expired - Fee Related
- 2011-11-11 SG SG2013035894A patent/SG190230A1/en unknown
- 2011-11-11 PE PE2013001063A patent/PE20140408A1/es not_active Application Discontinuation
-
2013
- 2013-05-09 IL IL226275A patent/IL226275A0/en unknown
- 2013-05-09 NI NI201300041A patent/NI201300041A/es unknown
- 2013-05-09 GT GT201300118A patent/GT201300118A/es unknown
- 2013-05-10 DO DO2013000104A patent/DOP2013000104A/es unknown
- 2013-06-02 EC ECSP13012678 patent/ECSP13012678A/es unknown
- 2013-06-03 ZA ZA2013/04042A patent/ZA201304042B/en unknown
- 2013-06-07 CR CR20130271A patent/CR20130271A/es unknown
- 2013-06-10 MA MA36005A patent/MA34732B1/fr unknown
- 2013-06-12 CO CO13140762A patent/CO6721010A2/es unknown
-
2014
- 2014-01-31 US US14/170,101 patent/US9302120B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201304042B (en) | Spiro-oxindole mdm2 antagonists | |
| IL229387A0 (en) | Antagonists to spiro-oxindole mdm2 | |
| IL219706A0 (en) | Spiro-oxindole mdm2 antagonists | |
| AP3607A (en) | Substituted imidazopyridazines | |
| AP3391A (en) | 2-Amino-4-arylthiazole compounds as TROA1 antagonists | |
| PT2927224T (pt) | Antagonistas de receptores | |
| SMT201700319T1 (it) | Pirrolidin-2-carbossammidi sostituite | |
| ZA201300994B (en) | Polypeptides | |
| GB201113558D0 (en) | Kraftfahrzeugkarosserie mit strukturverstarkter vorderrahmenanbindung | |
| ZA201303073B (en) | Construction block | |
| GB201116180D0 (en) | Kraftfahrzeug mit warnsystem | |
| AP3218A (en) | Compounds as bradykinin B1 antagonists | |
| ZA201304430B (en) | Substituted sodium-1h-pyrazole-5-olate | |
| EP2549872A4 (en) | TRPV4 Antagonist | |
| EP2599006A4 (en) | CONFIGURATION MANAGEMENT | |
| HK1183479A (en) | Spiro-oxindole mdm2 antagonists | |
| BR112013011766A2 (pt) | antagonistas espiro-oxindol mdm2 | |
| GB201014980D0 (en) | BAse for construction | |
| GB201004155D0 (en) | Shoulder rest | |
| TWM387087U (en) | can | |
| GB201008108D0 (en) | Helisuacer III | |
| GB201018136D0 (en) | Project |